$CRWV management said during the call it had plenty of cash and didn’t need to raise more debt - that triggered a short squeeze sending the stock 20% higher the next day
After the close, $CRWV announced they will raise $4b more in debt issuing a bond
This is securities fraud
$CRWV continues to use a subtle but effective trick to fool both humans and algorithms: by bringing the most recent year to the front, it's harder to notice that while its revenues 3x'd (something they greatly highlighted in the PR), losses in the same period got ~6x worse
The Greater Fool Report retweeted
$MRNA shares fall 9% premarket
This puppy has a long way to go down
This is a great short all the way to $80 a share.
The Greater Fool Report retweeted
David Eby was the last remaining anti-oil Premier in Canada.
Now every Premier across Canada supports the oil and gas industry and supports building pipelines.
The Trudeau-Guilbeault climate agenda was finally put down on Saturday night.
Get the shovels in the ground.
The Greater Fool Report retweeted
Wab Kinew: "Let's get rid of the Indian Act. You have nothing to lose but your chains."
The Greater Fool Report retweeted
UKMTO confirms the incident reported earlier today, tanker on fire 63NM southeast of Al-Faw, Iraq.
*possibly related to that fired detected by NASA FIRMS.
The Greater Fool Report retweeted
Lula teve 11 MILHÕES DE VOTOS A MAIS do 1º para o segundo turno.
Flávio teve cerca de 3 MILHÕES DE VOTOS A MAIS do 1º para o segundo turno.
Acho que isso é algo INÉDITO no planeta! Matematicamente é quase impossível isso acontecer.
Por que digo isso? Porque com mais de 130 milhões de brasileiros, 47% escolheram Flávio e 45% Lula.
14 milhões de pessoas deveriam seguir um mesmo padrão, ou padrão parecido, mas o que aconteceu foi que dos 14 milhões que votaram em outro candidato ou não foram votar no 1º turno, foram:
21% em Flávio
79% em Lula
Mesmo que essa quantidade estivesse no NORDESTE, seguindo padrão do nordeste não seria isso tudo! O nordeste deu 65% para o Lula.
Foi MUITO ESTRANHO essa quantidade toda para Lula.
The Greater Fool Report retweeted
$MRNA #Intismeran had 6 deaths vs 0 in placebo. Moderna investigators "claim" none related to their drug. The statistical chances are less than 10%. Given they refuse to reveal deaths' details, I would say the chances of that being true are 0. Stock should open Monday at $50.
The Greater Fool Report retweeted
$MRNA Investors Should Brace for More Whiplash
Even after its sharp fall, the drugmaker’s stock price assumes wild successes
wsj.com/health/pharma/modern…
The Greater Fool Report retweeted
Conservative Premier Designate Lorne Doerkson's victory in BC is a political earthquake.
The Greater Fool Report retweeted
Congratulations to @LDoerkson and the @Conservative_BC on a strong majority mandate to bring common sense Conservative principles to British Columbia.
I look forward to working together to save Canadians money and jobs, lock up criminals, reduce immigration, and put Canada first.
The Greater Fool Report retweeted
I appreciate that the OS hasn’t matured enough and the confidence interval is wide but a .77 HR is not a good look $MRNA
The Greater Fool Report retweeted
Updated financial take on Merck vaccine data in the @WSJ
Link to article is free
wsj.com/health/pharma/modern…
The leaked Merck vaccine data @myESMO underscore the challenges of the orchestrated theater of Act 1, company press release -> Act 2 hold data -> Act 3 public report at major meetings. Act 2, the hold phase, builds excitement for the company & discussion but inevitably there are data shared with KOLs and other stakeholders.
$MRNA rose 276% (🔼mkt cap $40+B) on press release and fell 18% (🔽$12B) on leak.
Seems unclear how this orchestration helps patients or actual research. To the extent there is peer review, it is done by the journals and not the meeting organizers themselves.
@adamfeuerstein @matthewherper
wsj.com/health/pharma/modern…
The Greater Fool Report retweeted
#ESMO26 | INTerpath-001: My Personal Perspective Ahead of the Presidential Session
This innovation deserves recognition: a groundbreaking result for personalized cancer vaccines. However, in patients with macroscopic stage III melanoma who are eligible for neoadjuvant IO, this trial does not establish the added value over contemporary perioperative strategies. Neoadjuvant treatment can produce substantial responses while allowing some patients to avoid adjuvant therapy.
The trial design I would prioritize is:
Neoadjuvant IO → surgery → standard adjuvant therapy ± a personalized vaccine in patients without a major pathological response.
Here, “failure to achieve a major pathological response” is a more appropriate selection criterion than “any residual disease.” Patients with minimal residual viable tumor who still achieve a major pathological response should not automatically receive additional treatment.
This approach would direct treatment intensification toward patients at higher risk of recurrence. The key biological uncertainty, however, is that IO-resistant residual disease is not necessarily vaccine-sensitive. Whether vaccination can overcome that resistance needs to be demonstrated.
This criticism should remain specific to that population: INTerpath-001 retains distinct clinical value for patients with stage IIB/IIC disease and those who underwent surgery without neoadjuvant therapy.
Bearish on $MRNA's valuation, not its clinical efficacy.
This ESMO slide highlights the elephant in the room: NADINA's neoadjuvant immunotherapy uses existing drugs, with shorter treatment duration, while Moderna's personalized vaccine faces manufacturing delays, logistical challenges and high costs.
No head-to-head efficacy comparison exists. But why assume massive peak sales when established alternatives already deliver strong outcomes?
Clinical success ≠ commercial success. $MRK $BMY
Replying to @adamfeuerstein
The most important slide. Neoadjuvant double the rate of severe toxicity vs $MRNA vaccine.
The Greater Fool Report retweeted
$MRNA bearish Shark retracement. Right on Cue.
The Greater Fool Report retweeted
Idk. No matter how you slice it, can't see how $MRNA is worth more than $100/sh.
I think probably closer to $60-$90. Maybe less.
I consider Evercore to be one of the “better” sell side firms when it comes to quality of biotech research.
Crazy that they are saying that even in a the absolute bull scenario, $MRNA shares are worth half the value they are trading at currently.
This is similar to the ~$88ish value that I came up with. And Rothschild, who has been the #1 most accurate firm on this stock, also has an $80 PT.
Reminds me of $PLTR in the tech sector a few years back. The short interest dynamics don’t really seem to indicate that this is really a “short squeeze” but more-so tech bros pumping something they think “can be huge.” But unlike $TSLA or $PLTR, this company does not have Elon Musk or Alex Karp running it or Peter Theil as a founder.
One of the most absurd situations. I fear the short play is just TOO obvious which is one of my concerns. But tech/ AI bros do always run out of steam eventually. Generalist funds that caught the memory shorts like $SNDK in June-July were highly rewarded.
The Greater Fool Report retweeted
Two days ago @MunchingMoez laid out his short thesis on Moderna.
Today the stock is down nearly 20%.
Pretty crazy. $MRNA
This is one of the most interesting conversations I have had on the podcast in a while.
I spoke with Anson Funds' @MunchingMoez to discuss how he trades hype and momentum, why he converted to bitcoin believer, and the lessons from putting $1 billion into bitcoin treasury companies.
We also discuss the AI trade, Korea’s memory boom, long activism, prediction markets, his $LION position, and SPACs.
YouTube: youtu.be/DqzbgKwuVxg?si=q-_Z…
Spotify: open.spotify.com/episode/42W…
Apple: podcasts.apple.com/us/podcas…
TIMESTAMPS:
0:00 - Intro
1:11 - Chasing hype, momentum & dealmaking
6:34 - Bitcoin: from deals to believer
9:02 - Bitcoin treasury companies & Strive’s preferred
15:40 - AI hype & sky-high valuations
17:53 - Private AI deals, tokenized stocks & 24/7 trading
21:23 - Trading against ChatGPT
24:50 - Finding your edge (SpaceX vs small caps)
28:46 - Korea, memory stocks & record put buying
34:27 - Short selling vs long activism
42:35 - Why Moderna could fall
45:16 - Prediction markets & social media sentiment
51:44 - Space & SPACs
54:56 - Canada, trade wars & funding Olympians
The Greater Fool Report retweeted
So you're telling me Moderna $MRNA lost $3.15 BILLION in the last 12 months
Its revenue collapsed from $19.3 billion in 2022 to $2.2 billion
And the stock still went from $30 to $245 this year
That's a $75 BILLION company trading at 34x sales while losing money
One trial result sent it up 177% in a day
One apparently leaked report sent it down 23% in a day
That's not investing.
That's a coin flip with a ticker symbol.
#ESMO Oncologists, if you don’t demand that neoantigen vaccines be studied against NEOadjuvant therapy, you’re doing the world and your patients a major disservice.
It’s not $MRK or $MRNA’s fault that the standard of care evolved after their study was launched, but we cannot reward “innovation” with tens of billions of dollars when that “innovation” might be replaced by simply giving the first 2-3 doses of medicine sooner, FOR ABSOLUTELY FREE. This is ridiculous.
$MRNA with the single most hilarious possible outcome in this study. EFS HR 0.58. Down the the hundredth, EXACTLY what *NEO*-adjuvant treatment with pembro yielded against adjuvant pembro (the nerfed comparator $MRNA studied against) in SWOG S1801.
What does this mean in English? $MRNA’s drug is showing the exact same benefit versus adjuvant pembrolizumab as NEOadjuvant pembrolizumab did.
Even more simply? If you just give patients a few doses of the pembrolizumab BEFORE you cut their cancer out, you do what $MRNA does for you, except with just the free tumor that’s already inside your body. No need to pay for this $400K drug.
And this makes rational sense, right? The whole point of $MRNA’s vaccine is to produce stuff that looks like the tumor.
You know what looks A LOT like the tumor does? THE FREAKING TUMOR!!!!!!
Absolutely poetic that $MRNA produced the EXACT HR benefit as neoadjuvant pembro did. Truly, the most hilarious possible outcome.
Now can we move on from this bullshit? $MRK and $MRNA should feel free to study their vaccine against the REAL standard of care now - NEOadjuvant immunotherapy.
From my perspective, this has been total fugaze, and an amateurish pump and dump worthy of much lesser enterprises.
$MRNA with the single most hilarious possible outcome in this study. EFS HR 0.58. Down the the hundredth, EXACTLY what *NEO*-adjuvant treatment with pembro yielded against adjuvant pembro (the nerfed comparator $MRNA studied against) in SWOG S1801.
What does this mean in English? $MRNA’s drug is showing the exact same benefit versus adjuvant pembrolizumab as NEOadjuvant pembrolizumab did.
Even more simply? If you just give patients a few doses of the pembrolizumab BEFORE you cut their cancer out, you do what $MRNA does for you, except with just the free tumor that’s already inside your body. No need to pay for this $400K drug.
And this makes rational sense, right? The whole point of $MRNA’s vaccine is to produce stuff that looks like the tumor.
You know what looks A LOT like the tumor does? THE FREAKING TUMOR!!!!!!
Absolutely poetic that $MRNA produced the EXACT HR benefit as neoadjuvant pembro did. Truly, the most hilarious possible outcome.
Now can we move on from this bullshit? $MRK and $MRNA should feel free to study their vaccine against the REAL standard of care now - NEOadjuvant immunotherapy.
From my perspective, this has been total fugaze, and an amateurish pump and dump worthy of much lesser enterprises.









































